How Gilead arrived at US$1,000 a pill price
What sets pricing is not R&D costs but potential insurer reaction and the chance to set a price benchmark: report
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
FROM the start, the miracle drug was expected to carry a high price tag: US$36,000 to treat each patient.
Over the two years leading up to the medicine's 2013 launch, Gilead Sciences Inc executives and advisers inched the number higher, to about US$65,000, then to US$81,000, then to US$84,000 - or US$1,000 a pill for the 12-week treatment - as they homed in on a price that was just below where they thought insurers would add restrictions for the breakthrough hepatitis C remedy.
Share with us your feedback on BT's products and services
TRENDING NOW
StarHub hands Ensign InfoSecurity control back to Temasek in S$115 million deal, books S$200 million gain
Singaporeans can now buy record amount of yen per Singdollar
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Keppel DC Reit posts 13.2% higher Q1 DPU of S$0.02833 on strong portfolio performance
